Literature DB >> 15741458

Remission in schizophrenia: proposed criteria and rationale for consensus.

Nancy C Andreasen1, William T Carpenter, John M Kane, Robert A Lasser, Stephen R Marder, Daniel R Weinberger.   

Abstract

New advances in the understanding of schizophrenia etiology, course, and treatment have increased interest on the part of patients, families, advocates, and professionals in the development of consensus-defined standards for clinical status and improvement, including illness remission and recovery. As demonstrated in the area of mood disorders, such standards provide greater clarity around treatment goals, as well as an improved framework for the design and comparison of investigational trials and the subsequent evaluation of the effectiveness of interventions. Unlike the approach to mood disorders, however, the novel application of the concept of standard outcome criteria to schizophrenia must reflect the wide heterogeneity of its long-term course and outcome, as well as the variable effects of different treatments on schizophrenia symptoms. As an initial step in developing operational criteria, an expert working group reviewed available definitions and assessment instruments to provide a conceptual framework for symptomatic, functional, and cognitive domains in schizophrenia as they relate to remission of illness. The first consensus-based operational criteria for symptomatic remission in schizophrenia are based on distinct thresholds for reaching and maintaining improvement, as opposed to change criteria, allowing for alignment with traditional concepts of remission in both psychiatric and nonpsychiatric illness. This innovative approach for standardizing the definition for outcome in schizophrenia will require further examination of its validity and utility, as well as future refinement, particularly in relation to psychosocial and cognitive function and dysfunction. These criteria should facilitate research and support a positive, longer-term approach to studying outcome in patients with schizophrenia.

Entities:  

Mesh:

Year:  2005        PMID: 15741458     DOI: 10.1176/appi.ajp.162.3.441

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  462 in total

Review 1.  Past and present progress in the pharmacologic treatment of schizophrenia.

Authors:  John M Kane; Christoph U Correll
Journal:  J Clin Psychiatry       Date:  2010-09       Impact factor: 4.384

2.  Time to treatment response in first-episode schizophrenia: should acute treatment trials last several months?

Authors:  Juan A Gallego; Delbert G Robinson; Serge M Sevy; Barbara Napolitano; Joanne McCormack; Martin L Lesser; John M Kane
Journal:  J Clin Psychiatry       Date:  2011-09-06       Impact factor: 4.384

3.  Evaluation of a multi-element treatment center for early psychosis in the United States.

Authors:  Sarah R Uzenoff; David L Penn; Karen A Graham; Sylvia Saade; Barbara B Smith; Diana O Perkins
Journal:  Soc Psychiatry Psychiatr Epidemiol       Date:  2012-01-26       Impact factor: 4.328

4.  Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.

Authors:  A P Rajkumar; B Poonkuzhali; A Kuruvilla; A Srivastava; M Jacob; K S Jacob
Journal:  Psychopharmacology (Berl)       Date:  2012-06-15       Impact factor: 4.530

5.  The PANSS should be rescaled.

Authors:  Stefan Leucht; Werner Kissling; John M Davis
Journal:  Schizophr Bull       Date:  2010-03-31       Impact factor: 9.306

Review 6.  Revisiting the diagnosis of schizophrenia: where have we been and where are we going?

Authors:  William R Keller; Bernard A Fischer; William T Carpenter
Journal:  CNS Neurosci Ther       Date:  2010-12-27       Impact factor: 5.243

7.  [Polypharmacy in schizophrenia].

Authors:  M Zink; S Englisch; A Meyer-Lindenberg
Journal:  Nervenarzt       Date:  2011-07       Impact factor: 1.214

8.  Gender Differences in Social Cognition: A Cross-Sectional Pilot Study of Recently Diagnosed Patients with Schizophrenia and Healthy Subjects.

Authors:  Guillem Navarra-Ventura; Sol Fernandez-Gonzalo; Marc Turon; Esther Pousa; Diego Palao; Narcis Cardoner; Merce Jodar
Journal:  Can J Psychiatry       Date:  2017-12-07       Impact factor: 4.356

9.  Modelling and forecasting Positive and Negative Syndrome Scale scores to achieve remission using time series analysis.

Authors:  Alka Sabharwal; Gurprit Grover; Sakshi Kaushik; K E Sadanandan Unni
Journal:  Int J Methods Psychiatr Res       Date:  2019-01-16       Impact factor: 4.035

10.  Negative symptoms and functioning during the first year after a recent onset of schizophrenia and 8 years later.

Authors:  Joseph Ventura; Kenneth L Subotnik; Michael J Gitlin; Denise Gretchen-Doorly; Arielle Ered; Kathleen F Villa; Gerhard S Hellemann; Keith H Nuechterlein
Journal:  Schizophr Res       Date:  2014-12-08       Impact factor: 4.939

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.